



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

**0 279 582
A3**

⑫

EUROPEAN PATENT APPLICATION

⑲ Application number: 88301112.4

⑤① Int. Cl. 4: **C12N 15/00 , A01K 1/00 ,
C12P 21/00 , A23C 9/20**

⑳ Date of filing: 10.02.88

③① Priority: 17.02.87 US 14952

④③ Date of publication of application:
24.08.88 Bulletin 88/34

⑥④ Designated Contracting States:
CH DE FR GB IT LI SE

⑥⑤ Date of deferred publication of the search report:
18.10.89 Bulletin 89/42

⑦① Applicant: **Baylor College of Medicine
Texas Medical Center 1200 Moursund
Avenue
Houston Texas 77030(US)**

⑦② Inventor: **Rosen, Jeffrey M.
3815 Grennoch Lane
Houston Texas 77025(US)**

⑦④ Representative: **Lucas, Brian Ronald et al
Lucas, George & Co. 135 Westhall Road
Warlingham Surrey CR3 9HJ(GB)**

⑥④ **DNA sequences to target proteins to the mammary gland for efficient secretion.**

⑥⑦ Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed.

EP 0 279 582 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 30 1112

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
O,X	J. CELL. BIOLOGY - TWENTY-SIXTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, Washington, D.C., 7th - 11th December 1986, vol. 103 (5 part 2), pages 313A, abstract no. 1161; K.F. LEE et al.: "Expression of the rat beta-casein gene in transgenic mice" ---	1-21	C 12 N 15/00 A 01 K 1/00 C 12 P 21/00 A 23 C 9/20
O,X D	TRANSCRIPTIONAL CONTROL MECHANISMS - UCLA SYMPOSIUM ON MOLECULAR AND CELLULAR BIOLOGY, 6th - 13th April, 1986, vol. 52, pages 313-323, Alan R. Liss, Inc.; C.A. BISBEE et al.: "DNA sequence elements regulating casein gene expression" * Whole article *	1-17	
X	TRENDS IN BIOTECHNOLOGY, vol. 5, no. 1, January 1987, pages 20-24, Elsevier Science Publishers, B.V., Amsterdam, NL; A.J. CLARK et al: "Pharmaceuticals from transgenic livestock" * Pages 22,23 *	1-21,29 -31	TECHNICAL FIELDS SEARCHED (Int. Cl.4)
X,P	WO-A-8 800 239 (PHARMACEUTICAL PROTEINS LTD) * Whole document *	1-3,5-9 ,11-13, 15-25, 29-31	C 12 N
E	EP-A-0 264 166 (INTEGRATED GENETICS INC.) * Whole document, especially page 6, lies 35-42 * --- -/-	1-25,29 -31	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19-07-1989	Examiner CUPIDO M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			



EP 88 30 1112

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
E	WO-A-8 801 648 (IMMUNEX CORP.) * Whole document, especially pages 10-12 * -----	1-3, 5-8, 12, 13, 15-25, 29-31	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19-07-1989	Examiner CUPIDO M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

THIS PAGE BLANK (USPTO)